Fabry International Prognostic Index: a predictive severity score for Anderson-Fabry disease. Issue 3 (7th February 2012)

• Record Type: Journal Article
• Authors: Hughes, Derralynn A; Malmenäs, Mia; Deegan, Patrick B; Elliott, Perry M; Ginsberg, Lionel; Hajioff, Daniel; Ioannidis, Alex S; Orteu, Catherine H; Ramaswami, Uma; West, Michael; Pastores, Gregory M; Jenkinson, Crispin
• Is Part Of: Journal of medical genetics. Volume 49:Issue 3(2012)
• Page Start: 212
• Page End: 220
• Publication Date: 2012-02-07
• Subjects: Fabry -- prognosis -- score -- outcome -- academic medicine -- calcium and bone -- cardiomyopathy -- cell biology -- clinical genetics -- cardiovascular medicine -- otolaryngology -- renal medicine -- metabolic disorders -- molecular genetics -- clinical genetics -- genetics; Medical genetics -- Periodicals; 616.042
• DOI: 10.1136/jmedgenet-2011-100407
• Languages: English
• ISSNs: 1468-6244

Abstract

Abstract : Background: Anderson-Fabry disease (AFD) is a disorder of glycosphingolipid metabolism resulting from deficiency of α-galactosidase A and accumulation of globotriaosylceramide. Presentation is heterogeneous and, despite guidelines for initiation of therapy, there is no basis for defining subgroups that will progress more rapidly, whether treated or not. The authors of this study used clinical and pathological data recorded on 1483 patients in the Fabry Outcome Survey, a large international registry, to develop a prognostic severity score. Methods: Parameters relevant to disease progression or outcome were initially selected, using variables that are readily available in clinical practice. Individual end points for renal, cardiac, neurological disease, and death were selected, and a composite end point developed. Potential prognostic variables were correlated with each end point, before multivariate analysis. Variables retaining significance were then used to construct organ specific and composite prognostic scores. Kaplan–Meier (KM) analysis, according to score, was performed for each end point. Results: Analysis demonstrated that it is possible to differentiate groups of patients with different outcome probabilities. Cardiac, renal and neurological end points could each be categorised into three separate groups. The 80% event-free survival for these groups differed by approximately 10 years. The overall composite score, the Fabry International Prognostic Index (FIPI), distinguished two distinct groups where the 50% event-free survival differed by 10 years. Conclusions: A prognostic scoring system for AFD has been developed and retrospective validation performed. The FIPI should prove to be a valuable tool in the counselling and management of AFD patients, and in comparative analyses of outcome using different therapies.